EcoDrugPlus

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSSTUG00000020599
Gene Symbol: IRAK4
3 Cross references
200 Possible Orthologues:

Interleukin-8-Like

Ensembl ID : ENSSTUG00000012638
Gene Symbol: LOC115201607
2 Cross references
179 Possible Orthologues:

Intermediate Conductance Calcium-Activated Potassium Channel Protein 4-Like

Ensembl ID : ENSSTUG00000010402
Gene Symbol: LOC115164439
2 Cross references
179 Possible Orthologues:

Intermediate Conductance Calcium-Activated Potassium Channel Protein 4-Like

Ensembl ID : ENSSTUG00000042405
Gene Symbol: LOC115177499
2 Cross references
179 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSSTUG00000024800
Gene Symbol: LOC115201696
3 Cross references
201 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSSTUG00000006327
Gene Symbol: LOC115153521
3 Cross references
201 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSTUG00000045246
Gene Symbol: IDH2
3 Cross references
184 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSTUG00000036862
Gene Symbol: IDH2
1 Cross references
200 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSTUG00000017237
Gene Symbol: IDH2
1 Cross references
184 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp] Cytoplasmic-Like

Ensembl ID : ENSSTUG00000010124
Gene Symbol: LOC115155568
3 Cross references
228 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp] Cytoplasmic-Like

Ensembl ID : ENSSTUG00000010572
Gene Symbol: LOC115160892
3 Cross references
227 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial

Ensembl ID : ENSSTUG00000028358
Gene Symbol: LOC115152014
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).